Sarepta's Gene Therapy Deaths Still Casting Shadow Over Elevidys Revenue Trajectory

Sarepta Therapeutics (SRPT) reports first-quarter 2026 earnings tomorrow, May 6, after market close, with analysts expecting $0.39 per share on the bottom line. The central question: can this rare disease biotech stabilize its financial trajectory after a volatile year marked by dramatic earnings swings and revenue headwinds? With the stock trading at $21.79 and options pricing an 8.66% expected move, investors face a high-stakes report that could either validate the recent technical recovery or trigger another sharp selloff.

Part 1: Earnings Preview

Sarepta Therapeutics is a biopharmaceutical company focused on developing precision genetic medicines for rare neuromuscular diseases, most notably Duchenne muscular dystrophy (DMD), using RNA-targeted therapeutics, gene therapy, and gene editing platforms. The company's approved DMD therapies—including Exondys 51, Vyondys 53, and Amondys 45—drive current revenues, while its gene therapy pipeline represents the long-term growth engine.

Earnings Snapshot: SRPT reports Q1 2026 results tomorrow after the close, with the Street modeling $0.39 per share versus a loss of $3.87 per share last quarter (Q4 2025). The consensus represents a dramatic +110.16% improvement compared to the -$3.84 loss reported in Q1 2025, suggesting analysts expect a return to profitability after two consecutive quarters of steep losses. Estimates span a wide range from -$0.71 to $1.84, reflecting significant uncertainty about near-term financial performance.

Three Key Themes Defining This Report:

1. Revenue Stabilization After Sharp Declines: The critical question is whether SRPT can halt the revenue erosion that has plagued recent quarters. Analysts had projected a 36% year-over-year revenue decline for Q1, and any commentary on DMD franchise performance—patient starts, treatment persistence, and geographic expansion—will be scrutinized intensely. Investors need to see evidence that the commercial foundation is stabilizing before they can have confidence in the earnings recovery narrative.

2. Path to Sustained Profitability: After posting losses of $3.87 and $3.84 in the past two quarters, the Street's expectation of a return to profitability hinges on either dramatic margin expansion, cost discipline, or favorable one-time items. Management's guidance on operating leverage and the sustainability of positive earnings will be critical, especially given the company's history of volatile quarterly results driven by R&D timing and milestone payments.

3. Gene Therapy Pipeline Progress: Beyond the quarterly numbers, investors are watching for updates on SRP-9001 and other gene therapy candidates, regulatory milestones, and any partnership developments. For a company trading near its 200-day moving average after a turbulent year, pipeline advancement could provide the catalyst needed to justify a higher valuation multiple, while setbacks could trigger another leg down.

Analyst Commentary: Wall Street remains deeply divided on SRPT heading into the print. The consensus rating sits at 3.19 (Hold territory) with a $21.78 average price target essentially matching the current stock price, suggesting analysts see limited near-term upside. However, the wide target range—from $5 to $38—reflects the binary nature of biotech investing, where pipeline success or failure can dramatically alter the investment thesis. Recent estimate revisions have been mixed, with the Q1 EPS consensus climbing from $0.39 currently versus prior expectations, but full-year 2027 estimates declining, indicating concerns about the durability of any near-term improvement.

Part 2: Historical Earnings Performance

Sarepta's recent earnings history reveals a company struggling with extreme volatility and consistent negative surprises. Over the past four quarters, SRPT has delivered two massive misses and two beats, creating a whipsaw pattern that has left investors uncertain about the company's true earnings power.

The most recent quarter (Q4 2025) saw SRPT report a loss of $3.87 per share against expectations of -$1.03, a staggering -275.73% miss that marked the second consecutive quarter of dramatic underperformance. This followed Q3 2025's modest +24.32% beat when the company posted -$0.28 versus the -$0.37 estimate. The volatility becomes even more pronounced looking at Q2 2025, when SRPT delivered a spectacular +117.95% beat with $1.70 in earnings against a $0.78 estimate—the only quarter of genuine profitability in the past year. Q1 2025 saw another catastrophic miss, with a -$3.84 loss versus the -$0.87 estimate, representing a -341.38% shortfall.

The pattern suggests SRPT's earnings are heavily influenced by timing of R&D expenses, milestone payments, and one-time items rather than steady operational performance. The company has missed estimates by an average of 171% in loss quarters while beating by an average of 71% in profitable quarters, indicating that when things go wrong, they go very wrong, but positive surprises can be equally dramatic. This binary outcome profile is typical of clinical-stage biotechs but creates significant risk for investors trying to position ahead of earnings. Tomorrow's report will test whether the Q2 2025 profitability was an anomaly or the beginning of a sustainable trend.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Sarepta typically reports after market close, meaning Day 0 captures anticipatory trading before results drop, while Day +1 reflects the market's first full session to digest the actual numbers.

Historical price action around SRPT earnings reveals dramatic volatility, with the stock prone to violent moves in both directions. The average absolute Day 0 move of 4.97% and Day +1 move of 10.74% underscore the high-stakes nature of these events, though the Day +1 figure is heavily skewed by the catastrophic -33.74% plunge following the November 2025 report and the -21.45% collapse after May 2025 earnings.

The most recent earnings cycle (February 2026) showed relatively muted action, with a +0.69% Day 0 move and -8.01% Day +1 decline, suggesting investors were braced for disappointment. The pattern over the past eight quarters shows SRPT is particularly vulnerable to sharp selloffs when results disappoint—four of the eight reports triggered Day +1 declines exceeding 5%, with two exceeding 20%. Conversely, positive surprises can generate meaningful upside, as seen in the +10.46% Day +1 rally following the August 2025 beat.

The wide intraday ranges—averaging 7.30% on Day 0 and 9.26% on Day +1—indicate significant two-way volatility as traders react to both the headline numbers and management commentary. Investors should be prepared for a potential double-digit percentage move in either direction following tomorrow's release, with the stock's recent history suggesting downside risk may be more pronounced than upside potential when results fall short of expectations.

Part 2.2: Options Market Expected Move

The options market is pricing a $1.89 expected move (8.66%) through Friday's May 8 expiration, which sits well below the stock's 10.74% average absolute Day +1 move following earnings. This suggests options traders may be underpricing the potential volatility, particularly given SRPT's history of 20%+ moves when results badly miss expectations. The 128.54% average implied volatility reflects elevated uncertainty, but the specific expected move appears conservative relative to the stock's demonstrated earnings sensitivity.

Part 3: What Analysts Are Saying

Wall Street maintains a cautious stance on Sarepta Therapeutics heading into tomorrow's report, with the consensus reflecting deep uncertainty about the company's near-term trajectory. The average analyst rating sits at 3.19 (Hold), with the $21.78 mean price target essentially matching the current $21.79 stock price, implying analysts see the shares as fairly valued with limited upside or downside from current levels.

The rating breakdown reveals a divided Street: 7 Strong Buys and 0 Moderate Buys on the bullish side, 15 Holds in the middle, and 5 analysts in sell territory (1 Moderate Sell, 4 Strong Sells). This distribution—with more than half the 27 analysts at Hold or below—suggests most of the Street is taking a wait-and-see approach rather than making aggressive bullish or bearish calls. The wide target range from $5 to $38 underscores the binary nature of the investment thesis, where bulls see potential for the gene therapy pipeline to drive substantial upside while bears focus on the commercial challenges and cash burn.

Sentiment has remained unchanged over the past month, with rating counts and the average recommendation holding steady at 3.19. This stability suggests analysts are waiting for the earnings report and management guidance before making meaningful changes to their views. The lack of recent upgrades or target raises indicates the Street isn't building in optimism ahead of the print, which could set up for positive surprises if results exceed the modest expectations. However, the clustering of targets near the current price also means there's limited cushion if the company disappoints again—particularly given the four Strong Sell ratings that likely carry much lower price targets within that $5-$38 range.

Part 4: Technical Picture

Sarepta enters earnings with improving technical momentum, though the setup remains fragile after a volatile year. The Barchart Technical Opinion currently reads 56% Buy, up from 40% Buy a week ago and 24% Buy a month ago, indicating strengthening near-term sentiment as the stock has climbed above key moving averages.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates near-term momentum is decidedly positive heading into the report
• Medium-term (50% Sell): Moderate sell signal suggests the intermediate-term trend remains under pressure despite recent gains
• Long-term (100% Buy): Strong buy signal reflects improving conviction in the longer-term uptrend

Trend Characteristics: The trend is characterized as Weak and Weakening, suggesting the recent rally lacks conviction and could be vulnerable to reversal if earnings disappoint.

The stock is trading above all major moving averages, including the 5-day ($21.37), 10-day ($21.03), 20-day ($21.30), 50-day ($19.68), 100-day ($20.22), and 200-day ($19.74). This represents a significant technical improvement from earlier in the year when SRPT was struggling below longer-term averages. The 50-day moving average has crossed above the 200-day, a potential bullish signal, though the modest separation suggests the trend change is still in early stages.

Key resistance likely sits near the $23-$24 zone based on the stock's recent trading range, while support should emerge at the 20-day moving average around $21.30 and more substantially at the 50-day near $19.68. The fact that SRPT has reclaimed all major moving averages provides a technical cushion heading into earnings, but the "Weak" and "Weakening" trend characterization suggests this support could fail quickly on a disappointing report. The overall setup is cautiously supportive—the stock has built a technical foundation above key averages—but the lack of strong conviction in the trend and the medium-term sell signal indicate investors should be prepared for significant two-way volatility. A beat could trigger a breakout above $24, while a miss could quickly send the stock back toward the $19-$20 support zone where the 50-day and 200-day moving averages converge.